Cargando…

Adjuvant Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer

Despite continuous improvement of diagnosis, surgical and adjuvant treatment procedures for non-muscle invasive bladder cancer (NMIBC), their natural development is still influenced by the high rates of tumor recurrence and progression. The study aims at assessing the value of adjuvant intravesical...

Descripción completa

Detalles Bibliográficos
Autores principales:	DRĂGOESCU, O., TOMESCU, P., PĂNUȘ, A., DROCAȘ, A., MARIA, C., ENACHE, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical University Publishing House Craiova 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006331/ https://www.ncbi.nlm.nih.gov/pubmed/24791205 http://dx.doi.org/10.12865/CHSJ.40.01.08

Ejemplares similares

Assessment of Extracorporeal Shock Wave Lithotripsy (ESWL) Therapeutic Efficiency in Urolithiasis
por: Tomescu, P., et al.
Publicado: (2009)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Analysis of Prostate Adenocarcinoma Histopathological Types in Relation to Tumor Grade
por: PĂNUŞ, ANDREI, et al.
Publicado: (2020)

The role of androgen receptors in vascular and cell proliferation of the prostate adenocarcinomas
por: Pănuş, Andrei, et al.
Publicado: (2020)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion
por: Drăgoescu, Petru Octavian, et al.
Publicado: (2023)

Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study
por: Arrabal Polo, Miguel Ángel, et al.
Publicado: (2023)

VEGF Immunoexpression in Prostate Adenocarcinoma
por: PĂNUŞ, ANDREI, et al.
Publicado: (2021)

The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer
por: Kostyev, Fedir, et al.
Publicado: (2021)

Genomic characterization of high-risk non-muscle invasive bladder cancer
por: Meeks, Joshua J., et al.
Publicado: (2016)

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
por: Grabe-Heyne, Kristin, et al.
Publicado: (2023)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer
por: Liem, Esmee I. M. L., et al.
Publicado: (2017)

Neutrophil to Lymphocyte Ratio (NLR)—A Useful Tool for the Prognosis of Sepsis in the ICU
por: Drăgoescu, Alice Nicoleta, et al.
Publicado: (2021)

Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?
por: Sargos, Paul, et al.
Publicado: (2016)

Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer
por: Lian, Jie, et al.
Publicado: (2018)

Molecular Landscape of Non-Muscle Invasive Bladder Cancer
por: Messing, Edward M.
Publicado: (2018)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2016)

Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial
por: Seiler, Roland, et al.
Publicado: (2023)

Non-muscle invasive bladder cancer risk stratification
por: Isharwal, Sumit, et al.
Publicado: (2015)

Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate
por: Han, Kyung-Sik, et al.
Publicado: (2015)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Treatment options in non-muscle-invasive bladder cancer after BCG failure
por: Brooks, Nathan A., et al.
Publicado: (2015)

Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
por: Lammers, Rianne J. M., et al.
Publicado: (2015)

One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients
por: De Sanctis, Vitaliana, et al.
Publicado: (2020)

Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA
por: Barocas, Daniel A., et al.
Publicado: (2012)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Follow-up in non-muscle invasive bladder cancer: facts and future
por: Witjes, J. Alfred
Publicado: (2020)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

The value of EORTC risk tables in evaluating recurrent non–muscle–invasive bladder cancer in everyday practice
por: Walczak, Rafał, et al.
Publicado: (2013)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians
por: Ślusarczyk, Aleksander, et al.
Publicado: (2021)

EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients
por: Borkowska, Edyta M., et al.
Publicado: (2013)

Review of current optical diagnostic techniques for non-muscle-invasive bladder cancer
por: Kołodziej, Anna, et al.
Publicado: (2016)

Non-muscle invasive bladder cancer: Are epicrises the ‘Bermuda Triangle’ of information transfer?
por: Lebentrau, Steffen, et al.
Publicado: (2017)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lo2v6ttltm1nn0qiuk77va0fv4